New drug combination for recurrent ovarian cancer after platinum
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—liposomal irinotecan (a chemotherapy) and enlonstobart (an immune-boosting antibody)—for ovarian cancer that came back within 6 months of platinum-based chemotherapy. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, aged 18–75 years
- You have epithelial ovarian, fallopian tube, or primary peritoneal cancer that came back within 6 months after your last platinum chemotherapy (but not within 4 weeks)
- You have received no more than two prior chemotherapy regimens besides platinum (certain maintenance therapies don't count)
- You have at least one measurable tumor that has not been treated with radiation or surgery
- Your organs (kidneys, liver, blood counts) are working adequately, and you are well enough for treatment (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and a low-dose chemo) for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It aims to find a new option when standard platinum chemo no longer works or cannot be used.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a combination of two standard chemotherapy drugs, cyclophosphamide and bevacizumab, with or without an immunotherapy drug called envafolimab. It aims to see if adding envafolimab helps shrink tumors better in people whose cancer has come back after platinum-based chemotherapy.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a combination of three drugs—liposomal irinotecan (chemotherapy), sintilimab (immunotherapy), and anlotinib (targeted therapy)—for people with recurrent or persistent ovarian clear cell carcinoma who have already tried platinum-based chemotherapy. The goal is to see if this triple therapy can shrink tumors or slow cancer growth.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.